Chronic Diabetic Foot Ulcer
Conditions
Keywords
Oneness, DCB-WH1, DCB-WH1-CP001, chronic, diabetic, foot ulcers, topical ointment
Brief summary
The primary objective of this Phase 2 study is to evaluate the efficacy of DCB-WH1 ointment in wound closure as compared to vehicle control when applied topically to chronic diabetic foot ulcers for 12 weeks. The secondary objective of this study is to collect safety information of DCB-WH1 ointment. This is a randomized, double-blind, parallel group, vehicle-controlled, multi-center study of DCB-WH1 ointment applied topically to grade 1 foot ulcers (according to Wagner grading system) in 50 subjects with diabetes mellitus.
Interventions
DRUGDCB-WH1 ointment
DCB-WH1 ointment (1.25%), topically applied twice daily
DRUGPlacebo
Placebo
Sponsors
Oneness Biotech Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Ages 20 or older with diabetes mellitus (Type 1 or 2) who has a cutaneous ulcer on the foot and present for at least 2 weeks 2. The target ulcer is classified as a grade 1 ulcer according to a modified Wagner system, which includes wounds involving the epidermis, the dermis, the hypodermis or the subcutaneous fat but not the tendon or joint capsule. The thickness of aforesaid layers wounds be approximately between 0.2 mm and 8 mm and is ranging in size between 3 and 15 cm2 post debridement. 3. An ankle brachial index ≥0.80. 4. The study ulcer should show infection control as judged by the investigator 5. The subject should be free of any necrotic or infected soft and bony tissue. 6. Signed informed consent form.
Exclusion criteria
1. Ulcers caused by venous or arterial insufficiency, osteomyelitis. 2. Poor nutritional status (albumin \< 3g/dl), poor diabetic control (HbA1c \> 10%), anemia (hemoglobin\<10 g/dL), a leukocyte counts \< 1,000/cumm. 3. Requiring prostaglandin treatment. 4. Requiring treatment with corticosteroids, immunosuppressive or chemotherapeutic agents, radiotherapy. 5. Presence of necrosis, purulence or sinus tracts that cannot be removed by debridement. 6. Presence of connective tissue disease, renal failure (\*eGFR≦30 ml/min/1.73m2), abnormal liver function (Aspartate Aminotransferase(AST), Alanine Aminotransferase(ALT)\>2.5x upper limit of normal range), malignancy. 7. vascularization surgery performed \<8 weeks before entry in the study. 8. A history of cerebrovascular events, coronary intervention (stent or coronary artery bypass graft (CABG)) or myocardial infarction, within 6 months prior to study. 9. Female patient who has a positive pregnancy test or who is breastfeeding or unwilling to use appropriate contraceptive methods during study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of complete ulcer closure | 12 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The time of healing rate and change in ulcer area | 12 weeks | time to ulcer closure, time to half ulcer closure, ulcer closure rate at endpoint, change and percentage change from baseline in ulcer size |
Countries
Taiwan
Outcome results
None listed